Connect with us

Fertility

The future of family: unveiling 45 cutting-edge advancements in IVF

By FinDBest IVF 

Published

on

The past couple of years have witnessed exciting advancements in the IVF/ART space, driven by cutting-edge technologies and a relentless pursuit of improving fertility outcomes. Here, FinDBest IVF offers a glimpse into some notable breakthroughs.

1. EMBRYOSCOPE (VITROLIFE) – iDAScore

  • Area: Artificial Intelligence (AI) in Embryo Selection
  • Description: Time-lapse imaging AI platform analysing embryo development for improved selection.
  • Impact: Predicts implantation potential, increasing pregnancy rates and reducing miscarriages.
  • URL: Vitrolife iDAScore

2. EXAMEN – SpermComet

  • Area: Non-invasive Sperm Selection
  • Description: DNA fragmentation assay for improved sperm selection.
  • Impact: Identifies sperm with minimal DNA damage, potentially increasing fertilisation and implantation rates.
  • URL: Examen SpermComet

3. EXCELLENT SCIENCE (Cherry Biotech) – MicroFSMA

  • Area: Microfluidics-based Sperm Analysis
  • Description: Automated method for semen analysis and quality sperm isolation.
  • Impact: Improves detection of male infertility and quality sperm isolation.
  • URL: MicroFSMA

4. OVERTURE LIFE – DaVitri, m|z, and ICSI.A

  • Area: Automation of Full ART Cycle
  • Description: Automated IVF process technologies to enhance consistency and affordability.
  • Impact: Reduces variability in outcomes and makes IVF more affordable.
  • URL: Overture Life

5. IVF 2.0 – SiD

  • Area: Computer-enabled Sperm Quality Tracker
  • Description: Computer vision-based sperm selection tool.
  • Impact: Analyses sperm motility more accurately than the human eye.
  • URL: IVF 2.0 SiD

6. IVF 2.0 – ERICA

  • Area: AI and Machine Learning for Embryo Selection
  • Description: Prioritises euploid embryos using AI without sampling or biopsy.
  • Impact: Enhances embryo selection for higher success rates.
  • URL: IVF 2.0 ERICA

7. TMRW LifeSciences – CryoRobot Select

  • Area: Automation of Tracking, Monitoring, and Storing of Frozen Embryos
  • Description: AI-integrated platform for tracking and storing frozen eggs and embryos.
  • Impact: Improves clinical outcomes and optimises treatment costs.
  • URL: TMRW CryoRobot Select

8. LIFE WHISPERER – Life Whisperer Genetics (LWG)

  • Area: AI-powered Euploid Pre-screening of Embryos
  • Description: AI evaluation of genetic normality in embryos.
  • Impact: Non-invasive pre-screening of embryos for genetic normality.
  • URL: Life Whisperer Genetics

9. LIFE WHISPERER – Life Whisperer Viability (LWV)

  • Area: AI-powered Embryo Selection
  • Description: AI evaluation of embryo viability for clinical pregnancy.
  • Impact: Enhances embryo selection for better pregnancy outcomes.
  • URL: Life Whisperer Viability

10. INITO – Inito

  • Area: Point-of-Care Fertility Testing
  • Description: Home-based hormone testing kit for fertility assessment.
  • Impact: Provides affordable and convenient fertility screening.
  • URL: Inito

11. Cooper Surgical Fertility Companies – RI Witness ART Management System

  • Area: Witness System for Monitoring ART Cycles
  • Description: Automated control system for monitoring sample and embryo handling.
  • Impact: Standardises the environment and minimises human error.
  • URL: RI Witness

12. HAMILTON THORNE, MICROPTIC – CASA (Computer-Assisted Sperm Analysis), SCA (Sperm Class Analyzer)

  • Area: Advanced Sperm Motility Analysis
  • Description: Enhanced motility and morphology assessment systems.
  • Impact: Provides detailed sperm quality data for better selection.
  • URL: Hamilton-Thorne CASA
  • URL: SCA

13. AVA WOMEN – The Ava Bracelet

  • Area: Wearables
  • Description: Predicts optimal implantation window through cervical secretion analysis.
  • Impact: Identifies the most receptive time for embryo transfer.
  • URL: Ava Women

14. NATERA – Panorama™ Test

  • Area: Non-invasive Preimplantation Genetic Testing (PGT)
  • Description: NIPT-based analysis of foetal DNA for genetic abnormalities.
  • Impact: Safer and less invasive option for PGT.
  • URL: Natera Panorama

15. CONCEPTION BIO – Invitro Gametogenesis (IVG)

  • Area: Human Eggs from Stem Cells
  • Description: Generates eggs from induced pluripotent stem cells.
  • Impact: Potential breakthrough in fertility preservation.
  • URL: Conception Bio

16. KITAZATO – Soft Microrobot

  • Area: Microrobot-guided Embryo Transfer
  • Description: Controls the implantation position during embryo transfer.
  • Impact: Increases pregnancy rates and prevents ectopic pregnancy.
  • URL: Kitazato Microrobot

17. OURA – Oura Ring

  • Area: Wearable Health and Fertility Trackers
  • Description: Tracks biometric data relevant to fertility cycles.
  • Impact: Provides personalised insights into menstrual cycles and ovulation windows.
  • URL: Oura Ring

18. FERTILIS – Micro Devices for IVF Techniques

  • Area: General Automation of ART Process
  • Description: Micro medical devices for enhancing IVF treatment quality.
  • Impact: Improves oocyte retrieval, ICSI performance, and more.
  • URL: Fertilis

19. EMBL-EBI – AlphaFold DB

  • Area: AI-powered Sperm Morphology Analysis
  • Description: AI-based protein structure prediction for sperm morphology assessment.
  • Impact: Offers high-resolution analysis of sperm structure.
  • URL: AlphaFold

20. OVAREPRED (Pekin University Third Hospital) – OvaRePred

  • Area: Online Model for Ovarian Reserve Assessment
  • Description: Predicts the quantity of potential female eggs suitable for fertilisation.
  • Impact: Aids in treatment planning and optimising outcomes.
  • URL: OvaRePred

21. IGENOMIX (VITROLIFE) – WES

  • Area: IVF Genomics
  • Description: Whole exome sequencing for analysing gene coding sequences.
  • Impact: Cost-effective technique for genetic analysis.
  • URL: Igenomix WES

22. VISCOFAN, IT3D GROUP, TISSUELABS, ADVANCED SOLUTIONS

23. FERTIL IBÉRICA – SpermVD

  • Area: Next-Generation Sperm Cryopreservation Techniques
  • Description: Vitrification process for improved sperm survival and motility.
  • Impact: Offers potential for longer sperm storage and improved fertilisation rates.
  • URL: Fertil Ibérica SpermVD

24. FLUIGENT – Microfluidics for Cell Biology

  • Area: Microfluidics for Cell Analysis
  • Description: Cell biology is crucial for medical innovation. Fluigent’s microfluidics technology integrates precise fluid flow control with microscopy, creating automated platforms for cell growth in physiologically relevant environments. This minimises error manipulation by automating fluid delivery at controlled rates.
  • Impact: Enhances accuracy and efficiency in cell biology experiments, facilitating better understanding and treatment of diseases.
  • URL: FLUIGENT – Microfluidics for Cell Biology

25. MICRONIT – Organ-on-a-Chip (OOC)

  • Area: Organ-on-a-Tube Microdevices
  • Description: Organ-on-a-chip devices simulate biological systems for in-vitro drug testing. Cells are cultured on membranes with separately controllable fluid flows, leading to more accurate biological representations than traditional methods. These resealable OOC flow cells allow cell seeding through standard protocols.
  • Impact: Provides more precise drug testing results, enhancing the drug development process.
  • URL: MICRONIT – Organ-on-a-Chip

26. ONI, BRUKER, WASATCH PHOTONICS, MALVERN PANALYTICAL, SPECTRA SOLUTIONS – Ultrasound-Guided TESA

  • Area: Non-invasive Testicular Sperm Extraction (TESA) with Ultrasound Guidance
  • Description: This technology offers a minimally invasive alternative to traditional sperm retrieval methods, using multiphoton microscopy, Raman spectroscopy, and optical coherence tomography for better visualisation and retrieval of sperm.
  • Impact: Potentially less painful and more efficient sperm retrieval method, improving patient comfort and outcomes.
  • URL: ONIBrukerWasatch PhotonicsMalvern Panalytical

27. MIM FERTILITY – FolliScan

  • Area: AI-powered Follicle Tracking and Ovulation Prediction
  • Description: AI software that analyses transvaginal ultrasound images to identify and measure follicles with high precision.
  • Impact: Improves accuracy in tracking ovulation, enhancing the chances of successful fertilisation.
  • URL: MIM FERTILITY – FolliScan

28. BERRY GENOMICS – NIPT-Based Analysis

  • Area: Non-invasive Prenatal Screening for Multiple Genetic Diseases
  • Description: Advanced NIPT technology that screens foetal DNA for a wide range of genetic abnormalities, beyond traditional panels.
  • Impact: Provides comprehensive prenatal genetic screening, leading to early detection and better management of genetic conditions.
  • URL: BERRY GENOMICS

29. Fairtility – CHLOE™

  • Area: Transparency in AI
  • Description: CHLOE™ is a transparent AI-based decision support tool that provides visibility into clinical and laboratory data to help improve IVF outcomes.
  • Impact: Enhances IVF success rates by offering detailed insights and data transparency to clinicians and prospective parents.

URL: Fairtility – CHLOE™30. ARWorks and The IVF Company – IVF Sim Pro

  • Area: Educational Tools with Virtual Reality (VR)
  • Description: VR software designed for technical training in ICSI and embryo biopsy, aimed at professionals, universities, and clinics.
  • Impact: Improves technical skills and training efficiency in IVF procedures through immersive virtual reality.
  • URL: IVF Sim Pro

31. Eggschain – Eggschain

  • Area: Blockchain Technology for IVF Patient Data
  • Description: Blockchain-integrated system for genomics, medical records, and biospecimen tracking, enabling patients to have greater control over their healthcare data.
  • Impact: Enhances data security and patient empowerment in managing healthcare information.
  • URL: Eggschain

32. Ovogene – Ovogene

  • Area: AI-Driven Donor Bank
  • Description: An international egg donor bank offering Genetically Certified Oocyte® technology, providing oocyte NGS screening and 100% euploid oocytes.
  • Impact: Increases success rates and reduces the need for multiple IVF attempts by ensuring high-quality oocytes.
  • URL: Ovogene

33. IVF-assistants.com – Skillsets

  • Area: AI-Driven Digital Assistants for Fertility Clinics
  • Description: Provides personalised access to information about ART and IVF services, helping patients understand their options and book consultations.
  • Impact: Enhances patient engagement and trust, improving consultation bookings and clinic-patient communication.
  • URL: IVF-assistants.com

34. inviTRA – Eeva Test

  • Area: Genomics for Optimal Embryo Selection
  • Description: Eeva test predicts which embryos have the greatest developmental potential using a time-lapse system attached to the incubator.
  • Impact: Improves embryo selection for transfer, enhancing the success rates of assisted reproduction treatments.
  • URL: inviTRA – Eeva Test

35. Lumiris – Metaphor™

  • Area: Embryo selection with metabolism data.
  • Description: Using metabolic imaging with AI-hyperspectral microscopy, the metabolic stress of embryos is assessed to determine its quality.
  • Impact: Improve selection of optimal embryos and therefore transfer success and fertilziation ratios.
  • URL:IBEC-Metaphor

36. Clue – Clue Birth Control, Clue Conceive

  • Area: Self-Managed Patient Care Using Smartphones (mHealth)
  • Description: App-based system for monitoring menstrual periods, ovulation, and PMS, offering numerous educational resources.
  • Impact: Empowers female patients to manage their reproductive health effectively using smartphone technology.
  • URL: Clue

37. ViOHealthTech – OvuSense OvuFirst, OvuSense OvuCore, and OvuSense Pro

  • Area: App-Based Patient Health Monitoring
  • Description: An app-based platform that helps screen for common health issues related to reproductive health, including ovulation tracking and fertility monitoring.
  • Impact: Provides comprehensive health monitoring, improving fertility tracking and assisting in managing reproductive health.
  • URL: ViOHealthTech

38. HERA Biotech – MetriDx

  • Area: Non-Surgical (Non-Invasive) Diagnostic Test for Endometriosis
  • Description: The world’s first non-surgical test for definitive diagnosis and staging of endometriosis.
  • Impact: Offers a less invasive and more accessible option for diagnosing and managing endometriosis.
  • URL: HERA Biotech

39. Labcorp – Preeclampsia Test

  • Area: Blood-based Screening Test
  • Description: The first screening test for assessing preeclampsia risk in the first trimester of pregnancy.
  • Impact: Enables early detection and management of preeclampsia, potentially improving maternal and fetal outcomes.
  • URL: Labcorp

40. EVOLUTIVE MEDICA – BreastDS, MiniPc Koios Medical, InferScholar, Airs Medical

  • Area: AI for Medical Image Analysis (Rx)
  • Description: AI-driven analysis and diagnostic technology for early and precise cancer detection.
  • Impact: Enhances accuracy and efficiency in cancer diagnostics, improving early detection and treatment outcomes.
  • URL: EVOLUTIVE MEDICA

41. Rhea – RheaLabs (including recently acquired Embryonics for AI-Driven Diagnostics)

  • Area: Technology Integration for Improved Patient Experience
  • Description: Integrated approach to patient engagement using AI and machine learning, enhancing clinic workflow and patient case management.
  • Impact: Provides a more seamless and meaningful patient experience, improving care quality and operational efficiency.
  • URL: Rhea – RheaLabs

42. AIVF – EMA Platform, ART Compass by AIVF

  • Area: AI Technology for Improved IVF Cycle Success and Management
  • Description: AI-powered IVF solutions for clinics, labs, and patients, including embryo evaluation, patient communication, and analytical tools.
  • Impact: Increases the certainty of successful IVF cycles by enhancing evaluation and communication processes.
  • URL: AIVF

43. Nilotech – Nilochecker

  • Area: State-of-the-Art Lab Equipment Calibration
  • Description: All-in-one reference instrument for controlling and calibrating critical laboratory equipment, such as incubators and warming systems.
  • Impact: Ensures accurate calibration and control, improving laboratory efficiency and reliability.
  • URL: Nilotech – Nilochecker

44. IBM and Ovum Health – IBM Watsonx Assistant

  • Area: Chatbot Assistant for Patient Communication and Management
  • Description: Custom AI applications for managing data sources and accelerating AI workflows, designed for enhanced patient communication and management in fertility clinics.
  • Impact: Streamlines patient interaction and clinic management, improving overall efficiency and patient satisfaction.
  • URL: IBM Watsonx

45. Spring Molecular Diagnostics – IVFinfo.AI

  • Area: ChatGPT-Like Site for IVF/ART Questions
  • Description: Multilingual website featuring an AI chatbot that answers questions about assisted reproduction (ART) and fertility.
  • Impact: Provides accessible and reliable information to patients, enhancing their understanding and decision-making in fertility treatments.
  • URL: AI

Pioneering frontiers in reproductive medicine

As the field of reproductive medicine continues to evolve, several pioneering areas of research are emerging. These cutting-edge advancements have the potential to revolutionise infertility treatments and offer new hope to individuals and couples facing reproductive challenges. Below, we highlight some of the most promising developments currently under investigation:

  • Mitochondrial Replacement Therapy: This experimental technique aims to prevent the transmission of mitochondrial diseases by replacing the mother’s mitochondria in the egg with healthy ones from a donor.
  • Artificial Womb Development: Artificial womb technology is under exploration for potential use in certain cases of infertility or high-risk pregnancies.
  • In Vitro Gametogenesis (IVG): Researchers are exploring ways to create sperm and egg cells from stem cells, which could offer new possibilities for infertile individuals and couples.
  • Nanotechnology in Reproductive Medicine: Nanotechnology holds promise in enhancing drug delivery systems, improving embryo culture conditions, and developing novel diagnostic tools for infertility.
  • 3D Bioprinting of Reproductive Tissues: Researchers are exploring the use of 3D bioprinting technology to create reproductive tissues, such as ovaries and uterine scaffolds, for transplantation or in vitro study, offering potential solutions for fertility preservation and restoration.
  • Non-Invasive Embryo Assessment Techniques: Non-invasive imaging modalities, such as optical coherence tomography (OCT) and time-lapse microscopy, are being explored for real-time monitoring and assessment of embryo development within the incubator, reducing the need for invasive embryo biopsy procedures.

These innovative approaches represent the forefront of reproductive research, promising to expand the possibilities of assisted reproduction and improve outcomes for patients worldwide.

The future is now: partnering with FinDBest IVF to realise your vision

The advancements outlined in this article paint a hopeful picture for the future of IVF/ART. While some technologies are still under development, many are already being implemented or can be brought to market faster through the right partnerships. This is where FinDBest IVF steps in.

FinDBest IVF: your partner for global expansion and innovation in IVF/ART

FinDBest IVF goes beyond connecting you with distributors; we’re your gateway to a world of possibilities. Our platform curates a network of service providers specializing in:

  • Market expansion services: Leverage market research firms to identify regions with the highest demand for your innovations.
  • Clinical trial management: Partner with experienced firms to navigate regulatory hurdles and conduct successful trials with leading fertility clinics.
  • Marketing and communication experts: Craft targeted campaigns that resonate with fertility clinics and healthcare professionals, ensuring your technology reaches the right audience.
The benefits of a comprehensive approach

Partnering with FinDBest IVF offers numerous advantages:

  • Faster time to market: Identify the right partners and navigate market complexities with greater efficiency.
  • Enhanced innovation: Collaborate with leading research institutions to bring groundbreaking technologies to market faster.
  • Streamlined communication: Connect with fertility clinics seeking solutions and build lasting relationships with key stakeholders.
FinDBest IVF: your partner in progress

The future of IVF/ART is bright. FinDBest IVF empowers you to foster innovation, build strong partnerships, and ensure your life-changing technologies reach the patients who need them most.

Join us and unlock the full potential of your IVF/ART solutions on a global scale. Let’s revolutionise the path to parenthood, together.

Entrepreneur

Onto Health acquires diagnostics software company Levy Health

Published

on

Onto Health has acquired Levy Health, a fertility software company providing precision diagnostics and patient intake for reproductive medicine.

The acquisition, fuelled by Onto Health’s US$20m Series A fundraise in April, supports its plan to build scalable, tech-enabled infrastructure for reproductive medicine.

Onto founder Roohi Jeelani, MD, called it the first of several moves in the company’s expansion strategy in a LinkedIn post, adding that there was “more coming soon”.

She said: “This isn’t just an acquisition, it’s proof of how we’re building Onto: physician-led, tech-enabled, and built to scale without losing the personal touch fertility patients deserve.”

Headquartered in Chicago, Onto Health combines evidence-based fertility care with artificial intelligence-driven diagnostics, clinical automation and longevity science.

AI-driven diagnostics use software to analyse patient information and support clinical decision-making, rather than replace clinicians.

Levy Health, founded in Berlin with US offices in San Francisco, helps medical providers identify endocrine disorders more quickly and helps clinics streamline fertility workups.

Endocrine disorders affect the body’s hormone system, which can influence ovulation, menstrual cycles and fertility.

Co-founder Caroline Mitterdorfer said joining Onto would expand Levy Health’s fertility care tools to more clinics and patients, helping physicians focus on patient care.

Onto opened its first clinic in Chicago in February, with plans for three more in the greater Chicago area.

The company said in April that it would use its new funding, led by Artis and Humania, to support additional operations in the US and expand into the Gulf Cooperation Council.

The Gulf Cooperation Council includes six Arab states bordering the Persian Gulf.

Continue Reading

Insight

Softening ovaries could extend fertility as women age, study suggests

Published

on

Softening ageing ovaries could help women remain fertile for longer, early animal research suggests.

Fertility declines with age for several reasons, including poorer egg quality, fewer ovarian follicles and the gradual stiffening of ovarian tissue.

Existing fertility treatments, including hormone therapy and in vitro fertilisation, mainly address hormonal imbalances or help eggs mature or become fertilised.

Scientists are now examining whether changing the physical structure of the ovaries could provide another route for future fertility treatments.

Stuart A. Cook, of the Cardiovascular and Metabolic Disorders Programme at Duke-National University of Singapore Medical School, published an accompanying commentary on the research.

Researchers led by Shixuan Wang at Huazhong University of Science and Technology in Wuhan, China, collected healthy ovarian tissue from younger, middle-aged and older women.

They also examined samples from patients with polycystic ovary syndrome, known as PCOS, premature ovarian insufficiency, or POI, and endometriosis.

PCOS is a hormonal condition that can disrupt ovulation. POI occurs when the ovaries stop working normally before the age of 40, while endometriosis causes tissue similar to the womb lining to grow elsewhere in the body.

Tests of protein levels and gene activity found higher levels of the inflammatory protein interleukin-11, or IL-11, in ageing and diseased ovaries.

In laboratory experiments, the researchers exposed ovarian fibroblasts to IL-11. Fibroblasts are cells that produce connective tissue.

The protein caused the cells to produce excess collagen, a structural material that can build up during scarring and make tissue stiffer.

The researchers then genetically modified mice so they could not respond to IL-11. The animals developed less ovarian stiffening and maintained better ovarian function as they aged.

Similar results were seen in mouse models of PCOS and POI caused by chemotherapy.

In the final part of the experiment, older mice and rats were injected with a nanoparticle treatment containing small interfering RNA, or siRNA, designed to switch off IL-11.

The treatment made the animals’ ovaries less stiff and improved fertility.

Pregnancy rates among older mice rose from 25 per cent to 50 per cent, while average litter sizes also increased.

More rats treated with the therapy became pregnant and produced larger litters.

The approach remains highly speculative and will require considerably more research before its safety or effectiveness in women can be established.

However, the researchers said blocking the inflammatory pathway could eventually form the basis of new fertility treatments.

They said: “We propose that anti-IL-11 therapy represents a promising translational strategy for delaying ovarian ageing.”

Continue Reading

Entrepreneur

Applications open for the third W Accelerate with Merck KGaA and M Ventures

Published

on

W Group has opened applications for W Accelerate with Merck KGaA and M Ventures, inviting reproductive and maternal health startups, scaleups and spinouts to pitch for direct access to global pharma partnership and strategic investment.

Selected companies will pitch on 5th October, competing for the chance to accelerate their growth through commercial partnerships, investment, or both.

This is the third time Merck KGaA, a global leader in reproductive health, has partnered with W Group on the programme, which exists to close the innovation and investment gap in women’s health by connecting the sector’s most promising startups directly with the corporates and investors positioned to scale them.

What Merck KGaA and M Ventures are looking for

This year’s call is focused on breakthrough solutions in female infertility, fertility preservation, adenomyosis, endometriosis, polyendocrine metabolic ovarian syndrome (PMOS), ovarian insufficiency, preeclampsia and pregnancy comorbidities.

New for this round, applicants choose between three pathways depending on what they need from the programme:

  • The Partnership Lane, for companies seeking commercial collaborations and strategic relationships
  • The Investment Lane, for founders looking to connect with investors and secure funding to scale
  • The Dual Lane, for innovators pursuing both partnership and investment opportunities

How the Accelerate event works

Selected companies get a 1:1 pitch practice session ahead of time, then a private 30-minute session with Merck KGaA and M Ventures leadership on the day itself, small-group sessions with regulatory and investment strategy experts, an “Ask Merck Anything” roundtable, and a VIP networking reception.

Key dates

  • Open call launches: 8th July
  • Open call closes: 2nd September
  • Notification of successful companies: 11th September
  • Pitch day: 5th October

Applications are open now at wplatform.typeform.com/to/KGzviBQM.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.